1 uk five year antimicrobial resistance strategy 2013-2018 (published 10 th september 2013) claire...

1

UK Five Year AntimicrobialResistance Strategy2013-2018(published 10th September 2013)

Claire Boville – Department of Health

European Antibiotic Awareness Day 2013 @ UCL

Wednesday 20th November

2

CMOs Annual Report (published March 2013)

The Chief Medical Officer (CMO) for England annual report set out:

• the scale of the global antimicrobial resistance (AMR) issue, • its implications for public health and;• the need for urgent action at a national and international level to

slow down and stem the spread of antimicrobial resistance.

The report highlighted the need for: • action on a global scale to ensure better surveillance data

nationally and internationally;• more work to preserve existing drugs and;• encourage the development of new antibiotics and rapid

diagnostics.

The UK Antimicrobial resistance strategy 2013-2018

3

Status of Antimicrobial Resistance in the UK• Multi-drug resistant bacteria are spreading in the UK and world wide.

• Increasing levels of resistant Gram negative bacteria are the most

pressing problem for the UK.

• Levels of resistance to carbapenem antibiotics, the last line drugs

used to treat infections caused by Gram negative bacteria, are low

but increasing.

Increasing resistance and a lack of new drugs means a risk of

infections that cannot be treated and more deaths

unless urgent action is taken.

The UK Five Year Antimicrobial Resistance Strategy 2013-2018

4

What is needed?

• Improved infection prevention and control,

• Strengthened antimicrobial stewardship to conserve the

effectiveness of the antibiotics we have,

• Improve understanding of transmission pathways with a focus

on human, animal and wider environmental aspects,

• Develop better diagnostics and more targeted treatments,

• Stimulate the development of new antimicrobials and novel

Treatments.


5

UK Five Antimicrobial Resistance Strategy (2013-2018)

• The UK Five year AMR strategy builds on the work of the first

UK AMR Strategy (2000) and has an holistic “one health“

focus.

• The strategy responds to the EU call to Member States to

produce national plans to tackle AMR

(2011 EU AMR Strategic Action Plan and the 2012 EU Council conclusions).

• Its content was informed by:• developments in other international fora (including WHO), • the challenges set out in CMOs 2012 annual report; and • consultation with a wide range of technical experts and others


6

Strategic Aims

The overarching goal of the Strategy is to slow the development and spread of AMR.

It will do this by focusing activities around three strategic aims to:

1. improve the knowledge and understanding of AMR.

2. conserve and steward the effectiveness of existing treatments,

3. stimulate the development of new antibiotics, diagnostics and novel therapies.

This will involve work in seven key areas for action, underpinned by work needed to strengthen the evidence base and improve our knowledge and understanding of AMR.


7

Seven Key Areas for Action

1. Improving infection prevention and control practices (PHE).

2. Optimising prescribing practice (PHE).

3. Improving professional education, training and public engagement (PHE).

4. Developing new drugs, treatments and diagnostics (DH).

5. Better access to and use of surveillance data (PHE).

6. Better identification and prioritisation of AMR research needs (DH).

7. Strengthened international collaboration (DH).

Note: Defra/VMD leads on all animal health aspects.


8

Implementation

• The DH, PHE and Defra/VMD lead work to implement the strategy.

• A new Interdepartmental High Level Steering Group has been

established to oversee implementation, working across all sectors.

• We are working with and through a wide range of stakeholders to:

influence opinion, galvanise support and mobilise action needed to effect positive change of the scale and pace required

to avert a return to a pre-antibiotic era


9

Interdepartmental High Level Steering Group (HLSG)It is charged with:

• developing an implementation plan to be published by April 2014,

• developing detailed outcome metrics, to be published by April 2014

• publishing an annual report on progress outputs and outcomes each year from November 2014


10

Outcome Measures

The HLSG, working with expert advisors, will develop detailed measures in the following areas:-

• trends in changes in resistance in key infections• assessing improvement in knowledge of antimicrobials and

their use,• assessing improvements in the quality of prescribing in

primary and secondary care compared to baseline,• monitoring use of antibiotics in animals – in particular, the 3

CIAs,• assessing global alignment in addressing AMR.


11

Priority areas for UK International Activity

• Strengthen surveillance arrangements - improving our ability to quickly identify new AMR threats or changing patterns in resistance,

• Extend the life of antibiotics by promoting better stewardship and conservation of antibiotic use in human, animal and wider environment,

• Stimulate a sustainable supply of antibiotics and development of innovative alternative treatments,

• Encourage collaboration to develop rapid and robust point of care diagnostics which can be used on a routine basis in clinical settings,

• Develop the evidence base to better understand the links between resistance in animals and humans and transmission pathways,

• Develop analysis of the economic burden of AMR for society,• Engage effectively with society to promote the social responsibility,• Use of behavioural science and communication mechanisms for take

action which will effect positive change.


12

European Antibiotics Awareness Day (EAAD) • Communication, Awareness raising and understanding of AMR is

crucial to effecting positive change.

• A central plank to this is our work to promote and support EAAD throughout the year.

• We are expanding the reach and impact of this work, for example

this year we have: • established a link to Self Care Week and engaged more

community pharmacists • sought to increase local participation through local

authorities;• secured greater involvement of veterinary colleagues


13

The Focus of AMR International work

The UK international work programme will aim to deliver the following:

• galvanise international collaboration to prevent the global spread of AMR (infection prevention and control, stewardship and conservation aspects),

• garner support for a “one health” approach to tackling AMR and developing evidence on the AMR transmission interface between human, animal and wider environment,

• Be instrumental in and take a leading role in work with UN and other key international bodies to develop innovative financing and regulatory (licensing) approaches which will help stimulate development of new antibiotics.


14

UK International Work

We continue to:

• press the EU and WHO to accelerate progress on implementation of AMR strategic action plans,

• Secure political commitment to tackle AMR through a wide range of fora such as G8, G20 and World Health Innovation Summit,

• Spearhead new initiatives to improve IPC, surveillance and stewardship capability in lower income countries and developing twinning projects across the Commonwealth


15

How we are doing thisThe UK is actively participating on AMR work in a wide range of international fora including:

• Promoted AMR issues during UK G8 Presidency at Science Ministers meeting,

• Sponsoring international Chatham House round table discussions on AMR

• Working with WHO and other UN bodies (OIE, FAO, Codex)• Working with EU Commission on surveillance, research,

legislative and drug pipeline issues to tackle AMR.• Working with the Commonwealth to support improved

surveillance and infection prevention and control,• WISH Conference – CMO chairing the panel on AMR which will

highlight areas requiring further international action,


16

We need to get to a point where:

• good infection prevention and control measures to help prevent infections occurring in the first place become the norm in all sectors of human and animal health,

• infections can be diagnosed quickly and the right treatment deployed,

• patients and animal keepers fully understand the importance of antibiotic treatment regimens and adhere to them,

• surveillance is in place which quickly identifies new threats or changing patterns in resistance, and

• There is a sustainable supply of new, effective antimicrobials for human use.


1 uk five year antimicrobial resistance strategy 2013-2018 (published 10 th september 2013) claire...

Documents